PMID- 17177199
OWN - NLM
STAT- MEDLINE
DCOM- 20080114
LR  - 20221207
IS  - 1091-4269 (Print)
IS  - 1091-4269 (Linking)
VI  - 24
IP  - 7
DP  - 2007
TI  - Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in 
      patients with major depression, comorbid anxiety, and residual depressive 
      symptoms: a randomized, placebo-controlled pilot study.
PG  - 487-94
AB  - This double-blind, placebo-controlled study examined the efficacy and 
      tolerability of quetiapine in combination with selective serotonin reuptake 
      inhibitors (SSRIs)/venlafaxine in 58 patients with major depressive disorder, 
      comorbid anxiety symptoms (HAM-A-14 score > or =14), and residual depressive 
      symptoms (HAM-D-17 score > or =18, CGI-S score > or =4). Patients had received an 
      SSRI/venlafaxine (at a predefined therapeutic dose) for > or =6 weeks. Overall, 
      62% (18/29) of quetiapine- and 55% (16/29) of placebo-treated patients completed 
      the study. The mean change in HAM-D and HAM-A total scores from baseline to Week 
      8 (primary endpoint) was significantly greater with quetiapine (mean dose 182 
      mg/day) than placebo: -11.2 vs. -5.5 (P=.008) and -12.5 vs. -5.9 (P=.002), 
      respectively. The onset of quetiapine efficacy (HAM-D/HAM-A/CGI-I) was rapid (by 
      Week 1) and continued through to Week 8. Significant differences (P<.05) from 
      baseline to Week 8 were observed between groups in 7/17 HAM-D (including feelings 
      of guilt, suicide) and 6/14 HAM-A items (including tension, cardiovascular 
      symptoms). Response (> or =50% decrease in total score) was higher for quetiapine 
      than placebo: HAM-D, 48% vs. 28% (not significant, NS); HAM-A, 62% vs. 28% 
      (P=.02). Remission (total score < or =7) was higher for quetiapine than placebo: 
      HAM-D, 31% vs. 17% (NS); HAM-A, 41% vs. 17% (NS). CGI-S, CGI-I, and the Global 
      Assessment Scale showed that quetiapine was significantly more effective than 
      placebo. For quetiapine, adverse events (AEs) were similar to those previously 
      observed; sedation/somnolence/lethargy was the most commonly reported. Here 
      quetiapine was shown to be effective as augmentation of SSRI/venlafaxine therapy 
      in patients with major depression, comorbid anxiety, and residual depressive 
      symptoms, with no unexpected tolerability issues. Further studies are warranted.
CI  - 2006 Wiley-Liss, Inc
FAU - McIntyre, Alexander
AU  - McIntyre A
AD  - Department of Psychiatry, Penticton Regional Hospital, Penticton, British 
      Columbia, Canada. amcintyre@telus.net
FAU - Gendron, Alain
AU  - Gendron A
FAU - McIntyre, Amanda
AU  - McIntyre A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Depress Anxiety
JT  - Depression and anxiety
JID - 9708816
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Cyclohexanols)
RN  - 0 (Dibenzothiazepines)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/*administration & dosage/adverse effects
MH  - Antipsychotic Agents/*administration & dosage/adverse effects
MH  - Anxiety Disorders/diagnosis/drug therapy/psychology
MH  - Comorbidity
MH  - Cyclohexanols/*administration & dosage/adverse effects
MH  - Depressive Disorder, Major/*drug therapy
MH  - Dibenzothiazepines/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Personality Inventory
MH  - Quetiapine Fumarate
MH  - Selective Serotonin Reuptake Inhibitors/*administration & dosage/adverse effects
MH  - Venlafaxine Hydrochloride
EDAT- 2006/12/21 09:00
MHDA- 2008/01/15 09:00
CRDT- 2006/12/21 09:00
PHST- 2006/12/21 09:00 [pubmed]
PHST- 2008/01/15 09:00 [medline]
PHST- 2006/12/21 09:00 [entrez]
AID - 10.1002/da.20275 [doi]
PST - ppublish
SO  - Depress Anxiety. 2007;24(7):487-94. doi: 10.1002/da.20275.